Arteriosclerosis and Thrombosis, Vol 11, 138-145, Copyright © 1991 by American Heart Association

ARTICLES

Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system

PM Sandset, H Lund, J Norseth, U Abildgaard and L Ose
Department of Medicine, Aker University Hospital, Oslo, Norway.

The present study was performed to determine the influence of pharmaceutical intervention on parameters of blood coagulation and fibrinolysis in hypercholesterolemic patients. Eighteen otherwise- healthy individuals with heterozygous familial hypercholesterolemia were treated with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (simvastatin, 40 mg daily) for 12-14 weeks followed by additional treatment with omega-3 fatty acids (equivalent to 4 g eicosapentaenoic acid/docosahexaenoic acid daily) for 6 more weeks. With simvastatin treatment, the mean decreases in total cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B (apo B) were 39%, 46%, and 36%, respectively. Only minor changes in high density lipoprotein (HDL) cholesterol and apo A-1 were recorded. omega- 3 fatty acids had minor additional effects. The most prominent effects on the blood coagulation system were the changes in extrinsic pathway inhibitor (EPI), which is the inhibitor of the factor VIIa-tissue thromboplastin complex. EPI activity decreased from a median of 153% to 111% (p less than 0.001) with simvastatin treatment and to 112% (p less than 0.001) on the combined regimen. EPI activity was significantly correlated with LDL cholesterol (r = 0.78), total cholesterol (r = 0.77), apo B (r = 0.65), and apo A-1 (r = 0.45). Multiple stepwise regression analysis showed that LDL cholesterol was the most important predictor of EPI activity, which suggests that a majority of EPI activity in plasma is associated with LDL. Moreover, the alteration in EPI activity was correlated closely with the corresponding alteration in LDL, which suggests a direct relation between a coagulation- inhibitor activity and a pharmaceutical lipid-related response.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review Ann Intern Med, October 21, 2003; 139(8): 670 - 682. [Abstract] [Full Text] [PDF]

				E.M. Bladbjerg, S.O. Skouby, L.F. Andersen, and J. Jespersen Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor Hum. Reprod., December 1, 2002; 17(12): 3235 - 3241. [Abstract] [Full Text] [PDF]

				A. C. Sposito and M. J. Chapman Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1524 - 1534. [Abstract] [Full Text] [PDF]

				P. B. Leurs, R. P. Stolk, K. Hamulyak, R. van Oerle, D. E. Grobbee, and B. H. R. Wolffenbuttel Tissue Factor Pathway Inhibitor and Other Endothelium-Dependent Hemostatic Factors in Elderly Individuals With Normal or Impaired Glucose Tolerance and Type 2 Diabetes Diabetes Care, August 1, 2002; 25(8): 1340 - 1345. [Abstract] [Full Text] [PDF]

				A. Kawaguchi, Y. Miyao, T. Noguchi, H. Nonogi, M. Yamagishi, K. Miyatake, Y. Kamikubo, K. Kumeda, M. Tsushima, A. Yamamoto, et al. Intravascular Free Tissue Factor Pathway Inhibitor Is Inversely Correlated With HDL Cholesterol and Postheparin Lipoprotein Lipase but Proportional to Apolipoprotein A-II Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 251 - 258. [Abstract] [Full Text] [PDF]

				A. Nordoy, K. H. Bonaa, P. M. Sandset, J.-B. Hansen, and H. Nilsen Effect of {omega}-3 Fatty Acids and Simvastatin on Hemostatic Risk Factors and Postprandial Hyperlipemia in Patients With Combined Hyperlipemia Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 259 - 265. [Abstract] [Full Text] [PDF]

				R. S. Rosenson and C. C. Tangney Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction JAMA, May 27, 1998; 279(20): 1643 - 1650. [Abstract] [Full Text] [PDF]

				Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation, April 21, 1998; 97(15): 1440 - 1445. [Abstract] [Full Text] [PDF]

				T. Kokawa, K.-i. Enjyoji, K. Kumeda, Y.-i. Kamikubo, M. Harada-Shiba, H. Koh, M. Tsushima, A. Yamamoto, and H. Kato Measurement of the Free Form of TFPI Antigen in Hyperlipidemia : Relationship Between Free and Endothelial Cell–Associated Forms of TFPI Arterioscler Thromb Vasc Biol, June 1, 1996; 16(6): 802 - 808. [Abstract] [Full Text]

				D. Zitoun, L. Bara, A. Basdevant, and M. M. Samama Levels of Factor VIIc Associated With Decreased Tissue Factor Pathway Inhibitor and Increased Plasminogen Activator Inhibitor-1 in Dyslipidemias Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 77 - 81. [Abstract] [Full Text]

				C. Lupu, F. Lupu, U. Dennehy, V. V. Kakkar, and M. F. Scully Thrombin Induces the Redistribution and Acute Release of Tissue Factor Pathway Inhibitor From Specific Granules Within Human Endothelial Cells in Culture Arterioscler Thromb Vasc Biol, November 1, 1995; 15(11): 2055 - 2062. [Abstract] [Full Text]

				P. Lesnik, C. Dentan, A. Vonica, M. Moreau, and M. J. Chapman Tissue Factor Pathway Inhibitor Activity Associated With LDL Is Inactivated by Cell- and Copper-Mediated Oxidation Arterioscler Thromb Vasc Biol, August 1, 1995; 15(8): 1121 - 1130. [Abstract] [Full Text]

				J.-B. Hansen, K. R. Huseby, N.-E. Huseby, P. M. Sandset, T.-A. Hanssen, and A. Nordoy Effect of Cholesterol Lowering on Intravascular Pools of TFPI and Its Anticoagulant Potential in Type II Hyperlipoproteinemia Arterioscler Thromb Vasc Biol, July 1, 1995; 15(7): 879 - 885. [Abstract] [Full Text]

				T. Kokawa, T. Abumiya, T. Kimura, M. Harada-Shiba, H. Koh, M. Tsushima, A. Yamamoto, and H. Kato Tissue Factor Pathway Inhibitor Activity in Human Plasma : Measurement of Lipoprotein-Associated and Free Forms in Hyperlipidemia Arterioscler Thromb Vasc Biol, April 1, 1995; 15(4): 504 - 510. [Abstract] [Full Text]